Challenge trials can be used to shorten clinical development plans successfully when certain criteria are met. For example, the quality of data obtained from challenge trials is in direct relation to the quality of the challenge agent.
With profound antigenic changes occurring in circulating virus strains, there is a pressing need for improved strains of challenge virus representative of prevalent, global subtypes.
Find out more on this exclusive webcast
Join us on this special webcast event, where our experts discuss how the newly developed and manufactured H3N2 challenge virus is being used in the fight against influenza.
To register your place, simply visit the link on this page and enter your details.